{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:14:48Z","timestamp":1794240888999,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007461","name":"Pezcoller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105847","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:38:47Z","timestamp":1760546327000},"page":"105847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"G.","family":"Antonarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Andreon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pellizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dellapasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105847_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105847_bib2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105847_bib3","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.105847_bib4","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105847_bib5","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105847_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.esmoop.2025.105847_bib7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105847_bib8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"10371","key":"10.1016\/j.esmoop.2025.105847_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105847_bib10","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105847_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105847_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104163","article-title":"Trastuzumab deruxtecan (T-DXd) \u00b1 pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07","volume":"10","author":"Andre","year":"2025","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105847_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.105847_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105847_bib15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105847_bib16","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105847_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105847_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105847_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"446","key":"10.1016\/j.esmoop.2025.105847_bib20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105847_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"suppl 68","key":"10.1016\/j.esmoop.2025.105847_bib22","article-title":"Trastuzumab Deruxtecan (T-DXd)-associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies","volume":"64","author":"Elu","year":"2024","journal-title":"Eur Respir J"},{"issue":"10265","key":"10.1016\/j.esmoop.2025.105847_bib23","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105847_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2025.105847_bib25","article-title":"Abstract P2-01-16: pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE project","volume":"31","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105847_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105847_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105847_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"NPJ Breast Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:06:20Z","timestamp":1764302780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2059702925017168"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105847","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105847"}}